AI
| Followers | 26 |
| Posts | 564 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2013 |
Sunday, April 07, 2024 5:28:19 PM
RWE of Icosapent Ethyl at ACC 2024. 38% MACE relative risk reduction IPE vs OM3. The authors are not even Amarin affiliated, so a truly independent study.
With Bhatt's vascular progenitor study, the new science continues to build in favor of IPE. ESC 2024 will be in London this year end of August. If we get more RWE in the form of MITIGATE, that should make a big difference for the remaining EU reimbursements. Happy to hear Amarin finally PR their European patent wins and exclusivity strength.
With Bhatt's vascular progenitor study, the new science continues to build in favor of IPE. ESC 2024 will be in London this year end of August. If we get more RWE in the form of MITIGATE, that should make a big difference for the remaining EU reimbursements. Happy to hear Amarin finally PR their European patent wins and exclusivity strength.
